Leishmania spp. and Trypanosoma cruzi are parasites belonging to the Trypanosomatidae family and the causative agents for two very important neglected tropical diseases (NTDs), namely leishmaniasis and trypanosomiasis, respectively. Together, they affect millions of people worldwide and the number of cases is constantly rising; thus, further effort on identifying and developing non-toxic, affordable and effective new drug is urgently needed to overcome this alarming situation. Exploring natural products from fungal and bacterial origin remains hitherto a valuable approach to find new hits and candidates for the development of new drugs against these protozoal human infections. Endophytes, which are microorganisms (fungal and bacterial) inhabiting plant tissues, represent a promising source, as they hold potential to produce a high number of distinct chemical scaffolds. These structurally diverse natural products have previously been successfully tested against a wide range of pathogenic microorganisms. The present review provides an update of endophytic compounds exerting anti-trypanosomal and anti-leishmanial effects and their predicted pharmacokinetic properties.

利什曼原虫属 和克氏锥虫是锥虫科的寄生虫，是两种非常重要的被忽视的热带病（NTD）的致病菌，分别是利什曼病和锥虫病。它们共同影响着全球数百万人，案件数量在不断增加。因此，迫切需要在鉴定和开发无毒，负担得起和有效的新药方面作进一步的努力，以克服这一令人担忧的情况。迄今为止，从真菌和细菌来源中探索天然产物仍然是寻找新的命中点和开发针对这些原生动物人类感染的新药物的候选方法。内生植物是居住在植物组织中的微生物（真菌和细菌），代表着有前途的来源，因为它们具有产生大量不同化学支架的潜力。这些结构多样的天然产物先前已成功针对各种病原微生物进行了测试。本综述提供了具有抗锥虫和抗利什曼作用的内生化合物及其预测的药代动力学特性的更新。